Press Releases – Global Alzheimer’s Platform Foundation

STATEMENT: THE GLOBAL ALZHEIMER’S PLATFORM FOUNDATION® PRESIDENT JOHN DWYER CONDEMNS THE CMS DECISION TO LIMIT A CLASS OF ALZHEIMER’S DRUGS AS “RATIONING CARE”

Posted on April 8, 2022 by Taylor Disselhorst

Washington, D.C. (April 7, 2022) – “Today, the Centers for Medicare and Medicaid Services (CMS) issued its final coverage ruling for an entire class of Alzheimer’s drugs. At its core, this National Coverage Decision (NCD) is not very different here from a flat-out denial of coverage. CMS continues to treat all Alzheimer’s patients differently than any other class […]

Biden Administration and Congress Take a Major Step to Accelerate Research to Treat and Cure Serious Illnesses

Posted on March 31, 2022 by Taylor Disselhorst

Modeled after DARPA, ARPA-H will incentivize innovative approaches to address some of America’s deadliest diseases Washington, D.C. (March 30, 2022) – A group of leading scientists and patient advocates today applauded the Biden Administration and Congress for making the Advanced Research Projects Agency for Health (ARPA-H) a reality. This new agency is designed to empower […]

THE GLOBAL ALZHEIMER’S PLATFORM FOUNDATION® ECHOES CONCERNS RAISED BY SENATORS WARNER AND MARKEY AND COLLEAGUES

Posted on March 23, 2022 by Taylor Disselhorst

CMS FAILS TO FAIRLY EVALUATE ALZHEIMER’S TREATMENTS Washington, D.C. (March 23, 2022) — Adding to the growing number of advocates calling on the U.S. Centers for Medicare and Medicaid Services (CMS) to reconsider an unprecedented National Coverage Determination (NCD) that discriminates against 6 million people with Alzheimer’s disease, U.S. Senators Mark R. Warner (D-VA) and […]

STATEMENT BY JOHN DWYER, PRESIDENT OF THE GLOBAL ALZHEIMER’S PLATFORM FOUNDATION® ON PRESIDENT BIDEN’S STATE OF THE UNION ADDRESS

Posted on March 1, 2022 by Taylor Disselhorst

Washington, D.C. (March 1, 2022) – “He did it again. From his victory speech in November 2020 and then again in his initial address to the nation in 2021, and then tonight in his most major address yet unveiling his ‘Unity Agenda,’ President Biden put Alzheimer’s disease near the top of the U.S. national public […]

Four Alzheimer’s Clinical Trial Volunteers Honored with National Citizen Scientist Awards® for Their Work in Search of a Cure

Posted on February 23, 2022 by Taylor Disselhorst

Global Alzheimer’s Platform Foundation® Honorees Include the First Canadian Recipient, Advocate to Veterans, Caregiver, and First Honoree with Parkinson’s Disease Contact: Andi Zucchi – andizucchi@rational360.com, 360-927-8767 Washington, DC (February 23, 2022) – The Global Alzheimer’s Platform Foundation (GAP) is honoring four clinical trial volunteers with 2021 National Citizen Scientist Awards. This year’s recipients include the […]

MedVadis Research Joins GAP-Net in Fight to Accelerate Alzheimer’s Treatment

Posted on February 14, 2022 by Taylor Disselhorst

MedVadis Research will join the Global Alzheimer’s Platform Foundation® Network (GAP-Net) of more than 100 global clinical trial sites Washington, D.C. (February 10, 2022) – The Global Alzheimer’s Platform Foundation® (GAP) announced that MedVadis Research has joined its network of more than 100 global clinical trial sites (GAP-Net), a team of leading academic and private […]

“Punitive, restrictive and unprecedented”: Global Alzheimer’s Platform Foundation President® John Dwyer Comments on CMS Draft National Coverage Determination

Posted on February 10, 2022 by Taylor Disselhorst

Dwyer calls on Centers for Medicare & Medicaid Services to provide coverage for the entire class of mAb drugs approved by the Food & Drug Administration and future drugs yet to be approved Washington, D.C. (February 11, 2022) – The Centers for Medicare & Medicaid Services (CMS) proposed plan to limit coverage of an entire […]

Clinicians and Researchers Urge CMS to Reform Decision to Limit Coverage of Alzheimer’s Treatments

Posted on February 10, 2022 by Taylor Disselhorst

Experts voice concerns over pre-judging promising treatments in the pipeline Today, five top Alzheimer’s clinicians and researchers called into question the preliminary proposal from the Centers for Medicare and Medicaid Services (CMS) to limit coverage FDA-approved monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease. The CMS proposal would alter the course of […]

Global Alzheimer’s Platform Foundation® Applauds Neurologists for Speaking Out Against Proposed CMS Plan to Restrict Coverage to Alzheimer’s Patients

Posted on February 2, 2022 by Taylor Disselhorst

New survey finds that 83% of neurologists believe that the safety and efficacy of an entire class of drugs should not be determined by the results of one medication. Washington, D.C. (February 2, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of […]

STATEMENT: Global Alzheimer’s Platform Foundation® Applauds Biogen for 18 Percent Diversity Recruitment Goal for Participants in Aduhelm Confirmatory Trial

Posted on January 27, 2022 by Taylor Disselhorst

Washington, D.C. (January 27, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, applauded the announcement today by Biogen Inc. that it would ensure that at least 18 percent of participants in its FDA mandated study will […]